Selected research
Industry Research
Oncology Treatment Drug Industry Research Report 2026
Market perspective
The global Oncology Treatment Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Oncology Treatment Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Oncology Treatment Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Oncology Treatment Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Oncology Treatment Drug include Takeda, Eisai, Teva, Sanofi, Johnson & Johnson, Novartis, Merck KGaA, Roche and Eli Lilly, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Oncology Treatment Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oncology Treatment Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oncology Treatment Drug Market by Company
Takeda
Eisai
Teva
Sanofi
Johnson & Johnson
Novartis
Merck KGaA
Roche
Eli Lilly
Pfizer
Bayer
Amgen
AbbVie
AstraZeneca
Otsuka
Merck & Co.
Ipsen
Gilead Sciences
Celgene
Bristol-Myers Squibb
Biogen Idec
Astellas
Oncology Treatment Drug Segment by Type
Immunotherapy (Biologic Therapy)
Chemotherapy
Hormonal Therapy
Targeted Therapy
Others
Oncology Treatment Drug Segment by Application
Respiratory/Lung Cancer
Prostate Cancer
Breast Cancer
Gastrointestinal Cancer
Blood Cancer
Others
Oncology Treatment Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Treatment Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Treatment Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Treatment Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oncology Treatment Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immunotherapy (Biologic Therapy)
- Chemotherapy
- Hormonal Therapy
- Targeted Therapy
- Others
Applications
- Respiratory/Lung Cancer
- Prostate Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Blood Cancer
- Others
Companies covered
- Takeda
- Eisai
- Teva
- Sanofi
- Johnson & Johnson
- Novartis
- Merck KGaA
- Roche
- Eli Lilly
- Pfizer
- Bayer
- Amgen
- AbbVie
- AstraZeneca
- Otsuka
- Merck & Co.
- Ipsen
- Gilead Sciences
- Celgene
- Bristol-Myers Squibb
- Biogen Idec
- Astellas
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oncology Treatment Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Immunotherapy (Biologic Therapy)
- 2.2.3 Chemotherapy
- 2.2.4 Hormonal Therapy
- 2.2.5 Targeted Therapy
- 2.2.6 Others
- 2.3 Oncology Treatment Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Respiratory/Lung Cancer
- 2.3.3 Prostate Cancer
- 2.3.4 Breast Cancer
- 2.3.5 Gastrointestinal Cancer
- 2.3.6 Blood Cancer
- 2.3.7 Others
- 2.4 Assumptions and Limitations
3 Oncology Treatment Drug Breakdown Data by Type
- 3.1 Global Oncology Treatment Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Oncology Treatment Drug Forecasted Market Size by Type (2027-2032)
4 Oncology Treatment Drug Breakdown Data by Application
- 4.1 Global Oncology Treatment Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Oncology Treatment Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oncology Treatment Drug Market Perspective (2021-2032)
- 5.2 Global Oncology Treatment Drug Growth Trends by Region
- 5.2.1 Global Oncology Treatment Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oncology Treatment Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Oncology Treatment Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Oncology Treatment Drug Market Dynamics
- 5.3.1 Oncology Treatment Drug Industry Trends
- 5.3.2 Oncology Treatment Drug Market Drivers
- 5.3.3 Oncology Treatment Drug Market Challenges
- 5.3.4 Oncology Treatment Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oncology Treatment Drug Players by Revenue
- 6.1.1 Global Top Oncology Treatment Drug Players by Revenue (2021-2026)
- 6.1.2 Global Oncology Treatment Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Oncology Treatment Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oncology Treatment Drug Head Office and Area Served
- 6.4 Global Oncology Treatment Drug Players, Product Type & Application
- 6.5 Global Oncology Treatment Drug Manufacturers Established Date
- 6.6 Global Oncology Treatment Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oncology Treatment Drug Market Size (2021-2032)
- 7.2 North America Oncology Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oncology Treatment Drug Market Size by Country (2021-2026)
- 7.4 North America Oncology Treatment Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oncology Treatment Drug Market Size (2021-2032)
- 8.2 Europe Oncology Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oncology Treatment Drug Market Size by Country (2021-2026)
- 8.4 Europe Oncology Treatment Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oncology Treatment Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Oncology Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oncology Treatment Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oncology Treatment Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oncology Treatment Drug Market Size (2021-2032)
- 10.2 South America Oncology Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oncology Treatment Drug Market Size by Country (2021-2026)
- 10.4 South America Oncology Treatment Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oncology Treatment Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Oncology Treatment Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oncology Treatment Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oncology Treatment Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Takeda
- 12.1.1 Takeda Company Information
- 12.1.2 Takeda Business Overview
- 12.1.3 Takeda Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.1.4 Takeda Oncology Treatment Drug Product Portfolio
- 12.1.5 Takeda Recent Developments
- 12.2 Eisai
- 12.2.1 Eisai Company Information
- 12.2.2 Eisai Business Overview
- 12.2.3 Eisai Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.2.4 Eisai Oncology Treatment Drug Product Portfolio
- 12.2.5 Eisai Recent Developments
- 12.3 Teva
- 12.3.1 Teva Company Information
- 12.3.2 Teva Business Overview
- 12.3.3 Teva Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.3.4 Teva Oncology Treatment Drug Product Portfolio
- 12.3.5 Teva Recent Developments
- 12.4 Sanofi
- 12.4.1 Sanofi Company Information
- 12.4.2 Sanofi Business Overview
- 12.4.3 Sanofi Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.4.4 Sanofi Oncology Treatment Drug Product Portfolio
- 12.4.5 Sanofi Recent Developments
- 12.5 Johnson & Johnson
- 12.5.1 Johnson & Johnson Company Information
- 12.5.2 Johnson & Johnson Business Overview
- 12.5.3 Johnson & Johnson Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.5.4 Johnson & Johnson Oncology Treatment Drug Product Portfolio
- 12.5.5 Johnson & Johnson Recent Developments
- 12.6 Novartis
- 12.6.1 Novartis Company Information
- 12.6.2 Novartis Business Overview
- 12.6.3 Novartis Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.6.4 Novartis Oncology Treatment Drug Product Portfolio
- 12.6.5 Novartis Recent Developments
- 12.7 Merck KGaA
- 12.7.1 Merck KGaA Company Information
- 12.7.2 Merck KGaA Business Overview
- 12.7.3 Merck KGaA Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.7.4 Merck KGaA Oncology Treatment Drug Product Portfolio
- 12.7.5 Merck KGaA Recent Developments
- 12.8 Roche
- 12.8.1 Roche Company Information
- 12.8.2 Roche Business Overview
- 12.8.3 Roche Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.8.4 Roche Oncology Treatment Drug Product Portfolio
- 12.8.5 Roche Recent Developments
- 12.9 Eli Lilly
- 12.9.1 Eli Lilly Company Information
- 12.9.2 Eli Lilly Business Overview
- 12.9.3 Eli Lilly Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.9.4 Eli Lilly Oncology Treatment Drug Product Portfolio
- 12.9.5 Eli Lilly Recent Developments
- 12.10 Pfizer
- 12.10.1 Pfizer Company Information
- 12.10.2 Pfizer Business Overview
- 12.10.3 Pfizer Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.10.4 Pfizer Oncology Treatment Drug Product Portfolio
- 12.10.5 Pfizer Recent Developments
- 12.11 Bayer
- 12.11.1 Bayer Company Information
- 12.11.2 Bayer Business Overview
- 12.11.3 Bayer Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.11.4 Bayer Oncology Treatment Drug Product Portfolio
- 12.11.5 Bayer Recent Developments
- 12.12 Amgen
- 12.12.1 Amgen Company Information
- 12.12.2 Amgen Business Overview
- 12.12.3 Amgen Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.12.4 Amgen Oncology Treatment Drug Product Portfolio
- 12.12.5 Amgen Recent Developments
- 12.13 AbbVie
- 12.13.1 AbbVie Company Information
- 12.13.2 AbbVie Business Overview
- 12.13.3 AbbVie Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.13.4 AbbVie Oncology Treatment Drug Product Portfolio
- 12.13.5 AbbVie Recent Developments
- 12.14 AstraZeneca
- 12.14.1 AstraZeneca Company Information
- 12.14.2 AstraZeneca Business Overview
- 12.14.3 AstraZeneca Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.14.4 AstraZeneca Oncology Treatment Drug Product Portfolio
- 12.14.5 AstraZeneca Recent Developments
- 12.15 Otsuka
- 12.15.1 Otsuka Company Information
- 12.15.2 Otsuka Business Overview
- 12.15.3 Otsuka Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.15.4 Otsuka Oncology Treatment Drug Product Portfolio
- 12.15.5 Otsuka Recent Developments
- 12.16 Merck & Co.
- 12.16.1 Merck & Co. Company Information
- 12.16.2 Merck & Co. Business Overview
- 12.16.3 Merck & Co. Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.16.4 Merck & Co. Oncology Treatment Drug Product Portfolio
- 12.16.5 Merck & Co. Recent Developments
- 12.17 Ipsen
- 12.17.1 Ipsen Company Information
- 12.17.2 Ipsen Business Overview
- 12.17.3 Ipsen Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.17.4 Ipsen Oncology Treatment Drug Product Portfolio
- 12.17.5 Ipsen Recent Developments
- 12.18 Gilead Sciences
- 12.18.1 Gilead Sciences Company Information
- 12.18.2 Gilead Sciences Business Overview
- 12.18.3 Gilead Sciences Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.18.4 Gilead Sciences Oncology Treatment Drug Product Portfolio
- 12.18.5 Gilead Sciences Recent Developments
- 12.19 Celgene
- 12.19.1 Celgene Company Information
- 12.19.2 Celgene Business Overview
- 12.19.3 Celgene Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.19.4 Celgene Oncology Treatment Drug Product Portfolio
- 12.19.5 Celgene Recent Developments
- 12.20 Bristol-Myers Squibb
- 12.20.1 Bristol-Myers Squibb Company Information
- 12.20.2 Bristol-Myers Squibb Business Overview
- 12.20.3 Bristol-Myers Squibb Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.20.4 Bristol-Myers Squibb Oncology Treatment Drug Product Portfolio
- 12.20.5 Bristol-Myers Squibb Recent Developments
- 12.21 Biogen Idec
- 12.21.1 Biogen Idec Company Information
- 12.21.2 Biogen Idec Business Overview
- 12.21.3 Biogen Idec Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.21.4 Biogen Idec Oncology Treatment Drug Product Portfolio
- 12.21.5 Biogen Idec Recent Developments
- 12.22 Astellas
- 12.22.1 Astellas Company Information
- 12.22.2 Astellas Business Overview
- 12.22.3 Astellas Revenue in Oncology Treatment Drug Business (2021-2026)
- 12.22.4 Astellas Oncology Treatment Drug Product Portfolio
- 12.22.5 Astellas Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst